– Live video webcast on Thursday, August 21st at 2:20 PM ET THE WOODLANDS, TX, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Thursday, August 21, 2025 at 2:2 ...

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption (“IDE”), and if approved, the commencement of U.S. clinical trials to support a De Novo FDA application THE WOODLANDS, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...

Autonomix Medical, Inc. (AMIX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individ ...

– Video webcast now available on-demand  THE WOODLANDS, TX, July 22, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Brad Hauser, Chief Executive Officer of Autonomix, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. For the event, Mr. Haus ...

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted ...

Core Insights - Autonomix Medical, Inc. is advancing precision nerve-targeted treatments and has announced a follow-on market expansion study phase ("PoC 2") for its proof-of-concept trial [1] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system [3] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [3] - This technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body [3] Technology Development - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which causes severe pain and lacks reliable treatment options [4] - The technology serves as a platform for addressing various indications, including cardiology, hypertension, and chronic pain management across a wide disease spectrum [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4]

Core Insights - Autonomix Medical, Inc. is expanding its clinical trials to include additional visceral cancer indications, effectively doubling its potential addressable market beyond pancreatic cancer pain [1][2] - The initiation of the PoC 2 phase follows positive results from the PoC 1 trial, which focused on patients with severe pancreatic cancer pain, indicating a strong foundation for multi-indication growth [2][3] - The company's technology platform has the potential to address a wide range of medical conditions, including cardiology, hypertension, and chronic pain management, with a concentrated focus on interventional cancer pain management applications [3][5] Company Overview - Autonomix Medical, Inc. is dedicated to advancing innovative technologies for diagnosing and treating diseases related to the nervous system [4] - The company's first-in-class platform includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [4][5] - The technology is currently investigational and has not yet received marketing clearance in the United States [5]

Core Viewpoint - Autonomix Medical, Inc. has received a significant patent that enhances its position in the nerve-focused therapeutics market, supporting its mission to provide minimally invasive treatments for various nerve-related conditions [1][2]. Group 1: Patent and Technology - The newly issued U.S. Patent No. 12,279,889 B2 ('889 patent) relates to advanced systems for evaluating and modifying neurological functions, including tools for accessing small vessels and treating cancerous tumors [1][3]. - The technology includes integrated sensors in microneedles for deep tissue access, multiband optical sensors for tissue viability, and control systems that adjust treatment based on feedback signals [3][4]. - Autonomix's platform utilizes a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling a precision-guided approach to treat chronic pain and other conditions [4][6]. Group 2: Market Opportunity and Clinical Trials - The patent strengthens Autonomix's intellectual property portfolio, which now includes over 80 issued patents, positioning the company in a multi-billion-dollar market opportunity [1][2]. - The company plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for its Sensing and RF Ablation System, targeting pancreatic cancer pain [5][7]. - The technology aims to address a wide range of conditions influenced by sympathetic nerve activity, including hypertension and chronic pain syndromes, with the potential for numerous applications across various medical fields [1][7].

Core Insights - Autonomix Medical, Inc. has received Ethics Committee authorization to expand its clinical trials for a proprietary ablation technology aimed at treating visceral cancer pain, building on initial success in pancreatic cancer pain [2][3] - The follow-on phase of the clinical program (PoC 2) is set to begin patient enrollment in June 2025, with the potential to double the addressable market by including additional visceral cancers [2][3][4] Group 1: Clinical Development - The PoC 2 phase will evaluate the safety and effectiveness of delivering transvascular energy to ablate problematic nerves, with a focus on interventional cancer pain management applications [2][4] - Initial trials in late-stage pancreatic cancer patients showed promising results, including significant pain reduction and decreased opioid use, indicating the technology's potential to transform cancer pain management [3][4] Group 2: Market Expansion - The expansion into visceral cancer pain aligns with Autonomix's strategy to create long-term value through multi-indication growth, addressing significant unmet needs in cancer treatment [3][4] - The technology platform has the potential to address various indications beyond cancer, including cardiology and chronic pain management, indicating a broad market opportunity [4][6][7] Group 3: Technology Overview - Autonomix's technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [6][7] - The investigational nature of the technology means it has not yet been cleared for marketing in the United States, highlighting its developmental stage [7]

Autonomix Medical, Inc. (AMIX) recently announced that it has been granted a key U.S. patent for its innovative catheter-based platform designed to sense and differentiate nerve signals in real-time. This technology represents a significant leap forward in the field of neuromodulation, with the potential to enhance treatment precision across a wide range of chronic conditions, including cancer and pain management. The platform enables both sensing and stimulation of nerves through a single device.With the b ...